Literature DB >> 8489210

Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis.

S Jacobson1, T Lehky, M Nishimura, S Robinson, D E McFarlin, S Dhib-Jalbut.   

Abstract

An increasing spectrum of diseases has been shown to be associated with the human T-cell lymphotropic virus type I (HTLV-I), most notably a chronic, progressive myelopathy termed HTLV-I--associated myelopathy/tropical spastic paraparesis and adult T-cell leukemia. HTLV-II is a close relative of HTLV-I and is structurally similar but molecularly distinct. This virus is endemic in Amerindian populations and a high seroprevalence rate has been observed in intravenous drug abusers. Here, for the first time, we have identified a patient with a chronic, progressive neurological disease clinically indistinguishable from HTLV-I--associated myelopathy/tropical spastic paraparesis from whom we have isolated and characterized HTLV-II in the absence of any other detectable human retrovirus. Antibodies to HTLV were detected in both serum and cerebrospinal fluid, with typical HTLV-II banding patterns on Western blots. HTLV-II viral sequences were detected in high copy number from peripheral lymphocytes by polymerase chain reaction techniques, and cloning and sequencing of this virus revealed a 99.5% homology with prototype HTLV-II. These results serve to alert the medical community to the possibility that in addition to HTLV-I, HTLV-II may be associated with a neurological disorder.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8489210     DOI: 10.1002/ana.410330411

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

1.  Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports.

Authors:  Silvia R Delgado; William A Sheremata; Andrew D Brown; Micheline McCarthy
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

Review 2.  The pathogenesis of the neurological complications of HIV-1 infection.

Authors:  B J Brew
Journal:  Genitourin Med       Date:  1993-10

3.  HTLV-II infection in the Western United States.

Authors:  B Hjelle
Journal:  West J Med       Date:  1994-06

4.  Human T-lymphotropic virus type 2 subtype b in a patient with chronic neurological disorder.

Authors:  Carolina Rosadas; Ana C P Vicente; Louise Zanella; Mauro J Cabral-Castro; José M Peralta; Marzia Puccioni-Sohler
Journal:  J Neurovirol       Date:  2014-09-03       Impact factor: 2.643

5.  Human T-lymphotropic virus type II seroprevalence among emergency department and clinic patients.

Authors:  D Agranoff; K Varney; H Khayam-Bashi; E L Murphy
Journal:  West J Med       Date:  1996-06

6.  HTLV-2 infection in injection drug users in King County, Washington.

Authors:  Joseph R Zunt; Ken Tapia; Hanne Thiede; Rong Lee; Holly Hagan
Journal:  Scand J Infect Dis       Date:  2006

7.  Infection with human T-lymphotropic virus types I and II results in alterations of cellular receptors, including the up-modulation of T-cell counterreceptors CD40, CD54, and CD80 (B7-1).

Authors:  C S Dezzutti; D L Rudolph; R B Lal
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

8.  Isolation and confirmation of human T-cell leukemia virus type 2 from peripheral blood mononuclear cells.

Authors:  Michael D Lairmore; Andy Montgomery
Journal:  Methods Mol Biol       Date:  2005

9.  Identification and characterization of an extended Tax protein in human T-cell lymphotropic virus type II subtype b isolates.

Authors:  D Pardi; J E Kaplan; J E Coligan; T M Folks; R B Lal
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

10.  Analysis of functional conservation in the surface and transmembrane glycoprotein subunits of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2.

Authors:  A R Rosenberg; L Delamarre; A Preira; M C Dokhélar
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.